Organon said OG-6219 did not beat a placebo in a mid-stage clinical trial whose main goal was to measure the change in pelvic pain caused by endometriosis. The twice-daily pill came from Organon’s 2021 acquisition of Forendo Pharma.
The post Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test appeared first on MedCity News.
